Condition (MeSH)
Torticollis
ClinicalTrials.gov lists 119 trials for Torticollis or a narrower condition beneath it. Ipsen has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
119 of the 119 trials are tagged with Torticollis itself; the rest are tagged with a narrower condition beneath it.
When did Torticollis trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 7 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 8 |
| 2018 | 4 |
| 2017 | 5 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 32 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 84 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Torticollis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 16 |
| Phase 3 | 13 |
| Phase 4 | 12 |
| Not applicable | 28 |
| Observational | 41 |
How many Torticollis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 12 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 1 |
| Completed | 82 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Torticollis trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ipsen | 11 |
| Allergan | 9 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 8 |
| Fondation Ophtalmologique Adolphe de Rothschild | 4 |
| Eisai Co., Ltd. | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Torticollis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Botulinum Toxin | 3 |
| PrabotulinumtoxinA-Xvfs | 2 |
| BOTULINUM TOXIN TYPE B | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| type A botulinum toxin | 30 |
| Transcranial Magnetic Stimulation | 2 |
| DaxibotulinumtoxinA for injection | 2 |
| Efficacy of Botox intramuscularly at Week 12 | 1 |
| Efficacy of Botox subdermally at Week 24 | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Torticollis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| overdose | 20 | 1 |
| Dysphagia | 12 | 7 |
| Acute Coronary Syndrome | 8 | 1 |
| Death | 7 | 1 |
| torticollis | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Torticollis? (125)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study. | Movement disorders clinical practice | 2025 | Yes |
| Abnormal Connectivity of the Head Neural Integrator in Cervical Dystonia. | Movement disorders : official journal of the Movement Disorder Society | 2025 | Yes |
| Motor development and sensory processing skills in infants with congenital muscular torticollis: a cross-sectional study. | European journal of pediatrics | 2025 | Yes |
| Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. | Neurology | 2024 | Yes |
| Spatiotemporal Gait Differences before and after Botulinum Toxin in People with Focal Dystonia: A Pilot Study. | Movement disorders clinical practice | 2024 | Yes |
Showing 5 of 125 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.